Market Snapshot
| Study Period: | 2018 - 2026 |
| Base Year: | 2020 |
| Fastest Growing Market: | Asia Pacific |
| Largest Market: | North America |
| CAGR: | 4.9 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
The Infectious Enteritis Treatment market is anticipated to grow with a CAGR of nearly 4.9%, during the forecast period.
Certain factors that are driving the market growth include the rising population with IBS and diarrheal cases due to infectious enteritis and intensive research and development activities and increasing fda approvals of infectious enteritis treatment drugs. According to the 2017 paper titles “Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: a Systematic Review and Meta-analysis”, foodborne illness affects 15% of the United States population each year and is a risk factor for irritable bowel syndrome (IBS).
The Centers for Disease Control and Prevention (CDC) categorizes foodborne illnesses into two groups i.e. illnesses caused by one of the currently known major pathogens, i.e., bacteria, viruses, parasites, and chemicals, and episodes of acute gastroenteritis caused by unknown agents or substances with unproven ability to cause illnesses.
The top pathogens include Norovirus, Salmonella, Clostridium perfringens, Campylobacter, and Staphylocuccus aureus. Many episodes of foodborne illness are marked by acute gastroenteritis. Common symptoms of acute gastroenteritis are diarrhea and vomiting. In addition, more serious complications such as colitis, bloodstream infection, meningitis, joint infection, kidney failure, and other problems can develop.
Globally, some groups of the population are at a higher risk for developing complications of gastroenteritis and foodborne illness, including the elderly, pregnant women, newborns, people undergoing treatments for cancer and autoimmune conditions, and those with Human Immunodeficiency Virus (HIV).
Scope of the Report
Enteritis refers to the inflammation of the small intestine. Infectious enteritis is the most common type and includes bacterial and viral enteritis. Eating or drinking contaminated food or water causes bacterial enteritis. Viral enteritis also occurs through eating or drinking contaminated food or water, and after contact with someone who has the virus. Viral enteritis usually goes away within a few days. A bacterial infection may require medical attention if it lasts for an extended period.
| By Route of Administration | |
| Oral | |
| Injectables |
| By Drug Type | |
| Antibiotics | |
| Antivirals | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Key Market Trends
Antiviral shows Lucrative Opportunity in the Global Infectious Enteritis Treatment Market
In most of the cases, people with viral gastroenteritis get better on their own without medical treatment. One can treat viral gastroenteritis by replacing lost fluids and electrolytes to prevent dehydration. In some cases, over-the-counter medicines may help relieve the symptoms. In some cases, adults take over-the-counter medicines such as loperamide (Imodium) and bismuth subsalicylate (Pepto-Bismol, Kaopectate) to treat diarrhea caused by viral gastroenteritis.
Doctors don’t prescribe antibiotics to treat viral gastroenteritis because antibiotics don’t work for viral infections. Hence, there are huge demands for effective antivirals for treating viral enteritis across the globe which is expected to drive the growth of the market.
As of now, two vaccines, which infants receive by mouth, are approved to protect against rotavirus infections i.e. RotaTeq and Rotarix.
To understand key trends, Download Sample Report
North America Dominates the Global Infectious Enteritis Treatment Market
Foodborne illnesses are a common cause of morbidity and sometimes death in the United States. Enteric infections are a major cause of diarrhea in the United States. Pathogens can cause diarrhea by elaboration of toxins that affect the intestinal mucosa or by direct invasion of the intestinal wall.
According to the CDC, clinical evaluation can provide important clues to aid in establishing a correct diagnosis in most patients with infectious enteritis. Appropriate cultures are necessary to confirm the diagnosis in most cases. Most types of infectious enteritis are self-limiting, but some pathogens can cause serious disease, requiring accurate diagnosis and suitable antibiotic therapy.
Appropriate precautions are being considered mandatory to prevent the spread of infectious diarrhea from occurring in the hospital environment. Dietary restrictions and appropriate hygiene are also observed during travel to foreign countries to reduce the chance of acquiring infectious enteritis. Such factors are propelling the market growth across the region.
To understand geography trends, Download Sample Report
Competitive Landscape
The global Infectious Enteritis Treatment market is competitive and consists of a few major players. Companies like Actelion Pharmaceuticals, BioGaia, Bristol-Myers Squibb, GlaxoSmithKline plc, Mayne Pharma, Novartis Pharmaceuticals, Pfizer Inc., Teva Pharmaceuticals, among others, hold the substantial market share in the market.
Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 The rising population with IBS and diarrhoea cases due to infectious enteritis
-
4.2.2 Intensive research and development activities and Increasing FDA approvals of infectious enteritis treatment drugs
-
-
4.3 Market Restraints
-
4.3.1 Several adverse effects associated with the treatment of infectious enteritis
-
4.3.2 Lack of awareness among people in developing countries
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Route of Administration
-
5.1.1 Oral
-
5.1.2 Injectables
-
-
5.2 By Drug Type
-
5.2.1 Antibiotics
-
5.2.2 Antivirals
-
5.2.3 Others
-
-
5.3 Geography
-
5.3.1 North America
-
5.3.1.1 United States
-
5.3.1.2 Canada
-
5.3.1.3 Mexico
-
-
5.3.2 Europe
-
5.3.2.1 Germany
-
5.3.2.2 United Kingdom
-
5.3.2.3 France
-
5.3.2.4 Italy
-
5.3.2.5 Spain
-
5.3.2.6 Rest of Europe
-
-
5.3.3 Asia-Pacific
-
5.3.3.1 China
-
5.3.3.2 Japan
-
5.3.3.3 India
-
5.3.3.4 Australia
-
5.3.3.5 South Korea
-
5.3.3.6 Rest of Asia-Pacific
-
-
5.3.4 Middle-East and Africa
-
5.3.4.1 GCC
-
5.3.4.2 South Africa
-
5.3.4.3 Rest of Middle-East and Africa
-
-
5.3.5 South America
-
5.3.5.1 Brazil
-
5.3.5.2 Argentina
-
5.3.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Actelion Pharmaceuticals
-
6.1.2 BioGaia
-
6.1.3 Bristol-Myers Squibb
-
6.1.4 GlaxoSmithKline plc
-
6.1.5 Mayne Pharma
-
6.1.6 Novartis AG
-
6.1.7 Pfizer Inc.
-
6.1.8 Teva Pharmaceuticals
-
*List Not Exhaustive -
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Infectious Enteritis Treatment Market market is studied from 2018 - 2026.
What is the growth rate of Infectious Enteritis Treatment Market?
The Infectious Enteritis Treatment Market is growing at a CAGR of 4.9% over the next 5 years.
Which region has highest growth rate in Infectious Enteritis Treatment Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Infectious Enteritis Treatment Market?
North America holds highest share in 2020.
Who are the key players in Infectious Enteritis Treatment Market?
Novartis Pharmaceuticals , Teva Pharmaceuticals , Pfizer Inc., GlaxoSmithKline plc. , Mayne Pharma are the major companies operating in Infectious Enteritis Treatment Market.
